News
US fertility education platform to support women in underserved communities
Wingwomen aims to widen access to fertility education and health coaching for reproductive health in the Southeast
A US reproductive health and fertility education platform has expanded into three Southeastern states to support underserved patient populations.
Wingwomen will widen access to emotional and nutritional support, virtual doula services, lifestyle, nutrition health coaching, reproductive health and fertility education to medically underrepresented women in Florida, Georgia and Louisiana.
According to the American College of Obstetricians and Gynecologists (ACOG), less than one-half of women in rural or exceptionally underserved areas in the US live within a 30-minute drive to the nearest hospital offering perinatal services.
Nearly one in five rural women of reproductive age reported the highest rates of delayed care or no medical care due to cost, with 23 per cent reporting no health insurance coverage.
“When we looked at the data, we realised we could deepen our impact by strategically including women who are most commonly overlooked by other telehealth market solutions,” says Adonica Shaw, Wingwomen founder and CEO.
“Millions of women are falling through the cracks because they either do not have insurance, live in a care desert or rural area, or in some cases, because they fall into the Medicaid patient population.
“It was important to make sure we carved a path that was inclusive of women regardless of their socioeconomic status.”
This strategic move, the founder says, will provide an equitable solution for women in the South who are more likely to be impacted by health disparities, including lack of access to community support, reproductive and sexual health education, ethnic, religious, and racial bias by practitioners, and lack of consistent health coverage throughout a woman’s entire reproductive health life cycle.
The announcement comes weeks after Wingwomen launched a series of reproductive health literacy programmes to support Gen Z and millennial women.
The programmes, introduced in February, feature a curriculum for preconception and postnatal health for women including those with polycystic ovary syndrome (PCOS), endometriosis, Hashimoto’s, diabetes, preeclampsia, advanced maternal age, sickle cell disease, as well as perimenopause.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Diagnosis2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







Pingback: MassMutual launches US$100m fund to invest in diverse-led companies - FemTech World